Results 201 to 210 of about 1,243,430 (291)
Building centaur responders: is emergency management ready for artificial intelligence? [PDF]
Whyte C, Haupt B'.
europepmc +1 more source
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan +5 more
wiley +1 more source
Sustainable development trade-offs shape the acceptability of climate mitigation scenarios
Parrado-Hernando G +13 more
europepmc +1 more source
Elephant barrier behaviors in response to conflict mitigation fences. [PDF]
Gonçalves D, Smith RJ, O'Neill HMK.
europepmc +1 more source
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao +5 more
wiley +1 more source
Design of an AI-driven secure 5G-SDN framework with federated reinforcement learning for anomaly detection, mitigation, and attack forensics. [PDF]
Shameli R, Rajkumar S.
europepmc +1 more source
ABSTRACT Traumatic spinal cord injury (TSCI) caused by sharp‐force penetration is exceptionally rare, and the use of high‐dose methylprednisolone (MP) remains highly controversial, especially beyond the conventional 8‐h treatment window. This case report describes a 30‐year‐old male with acute incomplete TSCI following a knife stab wound to the right ...
Honghong Wang +5 more
wiley +1 more source
Wildfires on a changing planet. [PDF]
Haas O, Prentice IC, Harrison SP.
europepmc +1 more source
Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin +11 more
wiley +1 more source

